Indexat a

Llicència i ús

Citacions

Cited 16 times in

Cited 15 times in

Altmetrics

Grant support

This research was funded by Nesapor Europa, which commercializes the Mareskit/Nesapor Rapid Antigen test. The authors also acknowledge the crowdfunding initiative #Yomecorono (https://www.yomecorono.com) and Foundation Dormeur for financial support for the acquisition of the QuantStudio-5 real-time PCR system and an Eclipse Ts2RFL inverted research microscope; NI-U is supported by grant PID2020-117145RB-I00 from the Spanish Ministry of Science and Innovation. MN-J and EM acknowledge funding from La Marato TV3 foundation, grant 202126-30-21. EP was supported by a doctoral grant from the National Agency for Research and Development of Chile (ANID 72180406). NG was supported by the postdoctoral grant Torres Quevedo from the Spanish Ministry of Science and Innovation (PTQ2019-010707). Unrelated to the submitted work JB and BC are founders and shareholders of AlbaJuna Therapeutics, S.L. Unrelated to the submitted work MN-J is founder and shareholder of Nano1Health S.L; BC is founder and shareholder of AELIX Therapeutics, S.L; JB reports institutional grants from MSD, HIPRA and Grifols; NI-U reports institutional grants from Pharma Mar, Grifols, Dentaid, Palobiofarma and HIPRA. Unrelated to the submitted work, EM has received grant support from Abbott GmbH & Co. KG. These funders was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.

Anàlisi d'autories institucional

Compartir

Performance of SARS-CoV-2 Antigen-Detecting Rapid Diagnostic Tests for Omicron and Other Variants of Concern

Publicat a:Frontiers In Microbiology. 13 810576- - 2022-05-10 13(), DOI: 10.3389/fmicb.2022.810576

Autors: Raich-Regue, D; Munoz-Basagoiti, J; Perez-Zsolt, D; Noguera-Julian, M; Pradenas, E; Riveira-Munoz, E; Gimenez, N; Carabaza, A; Gimenez, F; Saludes, V; Martro, E; Robert, N; Blanco, I; Paredes, R; Ruiz, L; Ballana, E; Clotet, B; Blanco, J; Izquierdo-Useros, N

Afiliacions

Resum

The SARS-CoV-2 antigen-detecting rapid diagnostic test (Ag-RDTs) is an easy-to-use diagnostic tool to identify the contagious individuals and reduce the new infections. However, to be effective, Ag-RDTs require the detection of distinct variants of concern (VOC) with high analytical sensitivity. Here, we found that the VOC diverge at the nucleocapsid protein used by four commercial Ag-RDTs for the viral detection. Relative to the original D614G variant, there was a 10-fold loss of detection for the Delta and Alpha variants in certain Ag-RDTs, a reduction above the threshold required to isolate the viable virus. However, Beta and Omicron variants did not lose the detection capacity. As the new VOC arise, successful contact tracing requires continuous monitoring of Ag-RDTs performance.

Paraules clau